Industry Newsregenerative medicineorthopedicsregentis biomaterialsexecutive hire
Regentis Appoints CFO To Lead Commercialization
|
5.1
Regentis Biomaterials appointed Ori Gon as chief financial officer and chief business officer on Feb. 4 to lead financial strategy and commercial development as its lead product GelrinC nears commercial launch in Europe and advances through a pivotal U.S. Phase III trial. GelrinC is a CE-marked, cell-free hydrogel implant for focal knee cartilage repair marketed as a cost-effective, 10-minute procedure with faster recovery and sustained pain relief.
Scoring Rationale
Moderate company-level news with official appointment; limited industry impact and shallow coverage reduces broader significance.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
